胃癌抗血管生成治疗的临床试验
Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer.
作者信息
Wu Li Cun, Zhang Wei Dong
机构信息
Toronto General Hospital, University Health Network (UHN), University of Toronto, Toronto, ON M5G 1L7, Canada.
Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, China.
出版信息
Gastroenterology Res. 2008 Dec;1(1):14-19. doi: 10.4021/gr2008.11.1250. Epub 2008 Nov 20.
Both malignant tumor growth and metastasis are dependent upon angiogenesis, a process of new blood vessel formation. Inhibition of this process by specific inhibitors might be able to control tumor growth and metastasis. Therefore, antiangiogenesis thereapy is considered a promising strategy and being studied worldwide. A wide variety of angiogenesis inhibitors have been identified and some of them are under clinical trials in the advanced patients with cancer including gastric cancer. This review summarizes the development and progress of angiogenesis inhibitors in recent decades, and discusses the future direction of antiangiogenesis research, and the potential antiangiogenic agents which are most likely to be translated into standard treatment for gastrointestinal cancer patients either alone or combined with other therapies.
恶性肿瘤的生长和转移均依赖于血管生成，即新血管形成的过程。通过特定抑制剂抑制这一过程或许能够控制肿瘤的生长和转移。因此，抗血管生成疗法被认为是一种有前景的策略，正在全球范围内进行研究。多种血管生成抑制剂已被确定，其中一些正在包括胃癌在内的晚期癌症患者中进行临床试验。本文综述了近几十年来血管生成抑制剂的发展与进展，并探讨了抗血管生成研究的未来方向，以及最有可能单独或与其他疗法联合转化为胃肠道癌患者标准治疗的潜在抗血管生成药物。
Zotero 插件